药物管线
Powered by Molecule Pro™
| Program | Modality | Indication | Discovery | Optimization | IND-enabling | Phase I/IIa | Partner |
|---|---|---|---|---|---|---|---|
 Wholly Owned | |||||||
MDR-001 | Small Molecule GLP-1RA | Obesity | Potential Best-in-Class | ||||
| Type 2 Diabetes | Potential Best-in-Class | ||||||
MRANK-023 | Undisclosed | Undisclosed | |||||
MRANK-002 | Undisclosed | Undisclosed | |||||
MRANK-101 | Undisclosed | Oncology | |||||
MRANK-501 | Undisclosed | Oncology | |||||
MRANK-603 | Undisclosed | Undisclosed | Out-Licensed | ||||
 Co-Developed | |||||||
2 programs | Undisclosed | Undisclosed | Public Biotech | ||||
8 programs | Undisclosed | Undisclosed | |||||
 Design as a Service | |||||||
EMRANK-016 | Allosteric Inhibitor | Oncology | PCC delivered | Public Biotech | |||
EMRANK-189 | Undisclosed | Undisclosed | Lead delivered | Public Biotech | |||